Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)

for
Ovarian Neoplasm, Depressive Symptoms, Quality of Life
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: Female

Age: 18+

Code: NCT05752448

Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

for
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer,
Location: Boston MA, Burlington MA, Hartford CT, Springfield MA,
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sex: Female

Age: 18+

Code: NCT05128825

Phase 2, Recruiting

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

for
Ovarian Cancer, Advanced Ovarian Carcinoma,
Location: Boston MA, Durham NC, Aurora CO, Boulder CO
Sponsor: Dana-Farber Cancer Institute

Sex: Female

Age: 18+

Code: NCT06710548

Recruiting

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

for
Ovarian Cancer
Location: Palo Alto CA
Sponsor: Stanford University

Sex: Female

Age: 18+

Code: NCT06646627

Phase 1, Recruiting

DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

for
Ovarian Neoplasms, Endometrial Neoplasms, Endometrial Cancer,
Location: Montreal
Sponsor: McGill University

Sex: Female

Age: 18+

Code: NCT02288676

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

for
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer,
Location: Boston MA, Commack NY, Baltimore MD, Ottawa, Toronto,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT05123482

Phase 1, Phase 2, Recruiting

A Study of DM002 in Patients With Advanced Solid Tumors

for
Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms,
Location: Huntersville NC, Houston TX, Oklahoma City OK,
Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Sex: All

Age: 18+

Code: NCT06751329

Phase 1, Phase 2, Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

for
Fallopian Tube Carcinosarcoma,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: Female

Age: 18+

Code: NCT04919629

Phase 2, Recruiting

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

for
Colorectal Neoplasms, Colorectal Cancer, Breast Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT02732860

Recruiting

With Love, Grandma ("Con Cariño, Abuelita") Pilot Study

for
Cancer, Breast, Cancer, Uterus, Cancer, Ovary, Obesity,
Location: Miami FL
Sponsor: University of Miami Sylvester Comprehensive Cancer Center

Sex: Female

Age: 21+

Code: NCT05721976

Recruiting

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

for
BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation,
Location: Boston MA, New York NY, Philadelphia PA, Durham NC,
Sponsor: University Medical Center Nijmegen

Sex: Female

Age: 25 - 50

Code: NCT04294927

Recruiting

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

for
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Location: Burlington MA, Orlando FL, Fort Worth TX,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT07743164

Phase 3, Recruiting

A Study of Sovilnesib in Subjects With Ovarian Cancer

for
High Grade Serous Adenocarcinoma of Ovary,
Location: Buffalo NY, Atlanta GA, Birmingham AL, Oklahoma City OK
Sponsor: Volastra Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06084416

Phase 1, Recruiting

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

for
NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial,
Location: Fairfax VA, Maumee OH, Portland OR
Sponsor: TwoStep Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07814248

Phase 1, Recruiting

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

for
Ovarian Neoplasms
Location: Montreal, Toronto
Sponsor: GlaxoSmithKline

Sex: Female

Age: 18+

Code: NCT07684612

Phase 3, Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

for
Ovarian Cancer
Location: Fairfax VA, Chicago IL, Omaha NE, San Antonio TX,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07278336

Phase 1, Recruiting

Autophagy Maintenance (AUTOMAIN)

for
Ovarian Cancer
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT06971744

Phase 2, Recruiting

Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries

for
Ovarian Cancer
Location: Toronto
Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT07539844

Recruiting

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

for
Ovarian Cancer
Location: New York NY, East Brunswick NJ, Los Angeles CA
Sponsor: Tubulis GmbH

Sex: Female

Age: 18+

Code: NCT07736937

Phase 1, Phase 2, Recruiting

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

for
Ovarian Cancer
Location: Boston MA, Philadelphia PA, Chicago IL, Fairway KS
Sponsor: Persevere Therapeutics Inc.

Sex: Female

Age: 18+

Code: NCT03854110

Phase 1, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial